- Company
- Hemlibra & Afstyla were released
- by Kim, Jin-Gu Jul 6, 2021 05:50am
- Domestic pharmaceutical companies have challenged the hemophilia treatment market one after another. JW Pharma released Hemlibra and SK Plasma released Afstyla in the last year. The domestic hemophilia treatment market is maintained by GC Pharma and Takeda. While Bayer, Sanofi, and Pfizer, which have challenged the market in the past, ar
- Product
- AZ-Pfizer vaccine mix is "confirmed safe and effective"
- by Jul 5, 2021 05:54am
- With community pharmacists who have received their first vaccination of AstraZeneca’s COVID-19 vaccine awaiting their second jab with the Pfizer vaccine this month, the health authorities announced that there are no safety concerns regarding the ‘mix-and-match' of the vaccines. The authorities explained that though mild side effects were ob
- Opinion
- [Reporter’s view] Request for suspension of execution
- by Kim, Jin-Gu Jul 5, 2021 05:54am
- The MOHW has announced that it will improve the system so that drug costs paid during the suspension of the enforcement of the drug reduction can be recovered. The plan calls for improvements to numerous revocation litigation and request for suspension of execution. request for suspension of execution in drug prices includes a lawsuit file
- Policy
- Suspension of Execution for Xarelto price cut continues
- by Kim, Jung-Ju Jul 5, 2021 05:54am
- Despite the two price cuts that were previously notified from the ex officio adjustment and expiry of the premium pricing application period, the price of the 4 strengths of Bayer Korea’s Xarelto tab. products will continue to be maintained as is for the time being. The company, which filed a suit against the government regarding the price c
- Company
- Ipsen established a union led by MZ generation
- by Jul 5, 2021 05:54am
- A labor union led by MZ generation (1980-2000s) is also being established in the pharmaceutical industry. According to the pharmaceutical industry on the 2nd, a labor union consisting of Ipsen sales workers officially launched on the 2nd after reporting on the 29th of last month. The union leader is Choi Chang-woo (35 years old), a youn
- Policy
- The price of 7 Seretide products will be reduced
- by Kim, Jung-Ju Jul 5, 2021 05:53am
- The government won the suit. But there is a possibility of change depending on the company's decision. Insurance prices for 7 items of asthma treatment Seretide by GSK will be lowered from the 2nd of next month. The government won the lawsuit against the company to cancel the reduction of the price. If the company disagrees with the ruling, t
- Company
- Metformin with excess NDMA was removed from the market
- by An, Kyung-Jin Jul 3, 2021 05:56am
- Most of the prescriptions for 31 types of Metformin, which had been suspended for detection of excess impurities a year ago, have disappeared. Sales of drugs, including Metformin, rose, but some companies were virtually kicked out from the market. There are many opinions that the government should take a more careful suspension of sales. A
- Company
- Lilly applies for listing of its fast-acting insulin Lyumjev
- by Eo, Yun-Ho Jul 3, 2021 05:56am
- The reimbursement benefit listing process for Lilly’s fast-acting insulin ‘Lyumjev’ will begin. According to industry sources, Lilly Korea had recently applied for the reimbursement of Lyumjev (insulin lispro). The drug, which has been approved in Korea on the 28th of last month, is attempting quicker market entry using the Drug Approv
- Company
- Takeda's Susoctocog alfa has been designated as a rare drug
- by Jul 3, 2021 05:56am
- Korea Takeda's "Susoctocog alfa," a bleeding treatment for patients with acquired haemophilia A, was designated as a rare drug by the MFDS on the 1st. Hemophilia is a major hemorrhagic disease caused by a lack of clotting factors in the blood due to mutations in genes located on the X chromosome. Hemophilia A, caused by lack of coagulation
- Company
- Martín Corcoll, Boehringer Ingelheim Korea's new GM
- by Jul 3, 2021 05:56am
- Boehringer Ingelheim Korea announced the appointment of Mart&237;n Corcoll as the company’s new GM and Head of Human Pharm as of July 1st. Since joining Boehringer Ingelheim in 2006, the new GM Corcoll had accumulated extensive experience and expertise in the industry, serving in various positions and divisions for over 15 years. Aft
